Grants paid by The Mog Project Inc
EIN 85-0767017 · Gaithersburg, MD · Form 990, Schedule I · NTEE G80
The Mog Project Inc of Gaithersburg, MD (EIN 85-0767017) reported 4 grants paid totaling $95,000 to 4 recipients in tax years 2023–2024, on Form 990, Schedule I. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$95,000
4 grants
Recipients
4
distinct organizations
Tax years
2023–2024
2 filings in the corpus
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2023 | 1 | $25,000 | — |
| 2024 | 3 | $70,000 | — |
Top recipients
The 4 recipients receiving the most from The Mog Project Inc, by grants paid, out of 4 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| Massachusetts General Hospital 04-1564655 | A | Boston, MA | 1 | $40,000 | 2024 |
| Brigham & Women's Hospital 04-2312909 | A | Boston, MA | 1 | $25,000 | 2024 |
| Northwestern University 36-2167817 | A | Evanston, IL | 1 | $25,000 | 2023 |
| Siegel Rare Neuroimmune Assoc 91-1780467 | A | Powell, OH | 1 | $5,000 | 2024 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 4 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | Massachusetts General Hospital Boston, MA | A | $40,000 | paid | Medical Research | 202503169349309470 |
| 2024 | Brigham & Women's Hospital Boston, MA | A | $25,000 | paid | Educational Award | 202503169349309470 |
| 2024 | Siegel Rare Neuroimmune Assoc Powell, OH | A | $5,000 | paid | Medical Research | 202503169349309470 |
| 2023 | Northwestern University Evanston, IL | A | $25,000 | paid | Steven Miller, PhD and team were awarded a grant to do a study to: (1) determine the effects of preventative tolerance induced by the PLG nanoparticles encapsulating the rhMOG protein versus the immunodominant MOG35-55 peptide on clinical rhMOG-EAE and on the resulting MOG-specific autoimmune responses. (2) To determine the effects of therapeutic tolerance induced by PLG nanoparticles encapsulating rhMOG protein versus the immunodominant MOG35-55 peptide on clinical rhMOG-EAE and accompanying MOG-specific immune responses. Future Objective: It is anticipated that the results will propel future human clinical testing of their novel PLG nanoparticle immune tolerance-inducing platform for treatment on MOGAD and other autoimmune disease. | 202413099349301971 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990 | 2024 | 2024-12-31 | not stated | 2024v5.2 | 202503169349309470 |
| 990 | 2023 | 2023-12-31 | not stated | 2023v5.0 | 202413099349301971 |
Derived from IRS Form 990 e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/850767017.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.